BUY Zydus Lifesciences Limited — Sachin Janardan Sarvade, IDBI Capital Markets and Securities

Entry₹1,210.7Inferred
Target₹1,455
Total upside +20.18%
Stop loss₹1,079-10.88% risk
CMP₹1,200.511h ago
Active-0.84%+21.20%upside left 13d left

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 30 Sept, 3:28 am IST
8 supporting2 neutral0 opposing
Supports the BUY call (8)

MACD above its signal line — bullish momentum

Technicals · macd·29 Sept · today

Past week's volume 1.6× the 30-day average

Technicals · volume·29 Sept · today

6 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·29 Sept · today

The USFDA concluded a cGMP inspection at the company's SEZ II manufacturing plant in Ahmedabad with only one observation and no data integrity issues.

BSE · Company Update·28 Sept · yesterday

(opens in new tab)

Zydus Lifesciences says USFDA inspection at New Jersey office concludes with nil observations

NewsCnbc-Tv18·26 Sept · 3d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.